Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Orbiteratec (funding) | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Novel Coronavirus is defined to be the cause of COVID-19, recently. It's known that COVID-19 goes with excessive immune reaction of human body in severe cases. The investigators hypothesize that quercetin, as a strong scavenger and anti-inflammatory agent, can be effective on both prophylaxis and treatment of COVID-19 cases. Therefore, the aim of this study to evaluate the possible role of quercetin on prophylaxis and treatment of COVID-19.
Novel Coronavirus is defined to be the cause of COVID-19, recently. It's known that COVID-19 goes with excessive immune reaction of human body in severe cases. Quercetin is reported to be effective on treatment and prophylaxis of other SARS like coronavirus infections, as a strong antioxidant and scavenger flavonoid without any adverse events. Upon this data, the investigators hypothesize that quercetin can be effective on both prophylaxis and treatment of COVID-19 cases. Therefore, the aim of this study to evaluate the possible role of quercetin on prophylaxis and treatment of COVID-19.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| non-quercetin group | No Intervention | Participants, who accept to enroll the study without having quercetin prophylaxis and who do not have a history of COVID-19, will be in this group. | |
| quercetin prophylaxis group | Active Comparator | Participants, who takes a daily dose of 500mg quercetin and who not have a history of COVID-19, will be in this group. |
|
| quercetin treatment group | Active Comparator | Participants, who takes a daily dose of 1000mg quercetin and who are proven cases for COVID-19, will be in this group. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Quercetin Prophylaxis | Dietary Supplement | a daily dose of quercetin (500mg) will be taken by non-COVID-19 intervention group 1 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of COVID-19 calculated using a questionnaire | Prevalence of COVID-19 in prophylaxis and sham group will be calculated using a questionnaire including hospital records | 3 months |
| Standardized Mortality rate | Mortality rate will be compared between two groups | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Morbidity rate | Morbidity rates besides recovery rates from COVID-19 will be documented | 3 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kanuni Sultan Suleyman Training and Research Hospital | Istanbul | 34303 | Turkey (Türkiye) |
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Quercetin Treatment | Dietary Supplement | a daily dose of quercetin (1000mg) will be taken by proven COVID-19 cases intervention group 2 |
|
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |